Natixis Advisors LLC Has $31.29 Million Stock Position in Cencora, Inc. (NYSE:COR)

Natixis Advisors LLC lifted its stake in Cencora, Inc. (NYSE:COR) by 3.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 139,028 shares of the company’s stock after buying an additional 5,198 shares during the quarter. Natixis Advisors LLC’s holdings in Cencora were worth $31,292,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of COR. New Millennium Group LLC bought a new stake in Cencora in the second quarter valued at $26,000. TFO Wealth Partners LLC bought a new stake in shares of Cencora in the 1st quarter worth about $30,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora in the 2nd quarter worth about $30,000. Concord Wealth Partners acquired a new stake in shares of Cencora during the 3rd quarter worth about $30,000. Finally, LRI Investments LLC bought a new position in Cencora during the 1st quarter valued at about $31,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on COR. Wells Fargo & Company raised their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Evercore ISI raised their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $271.20.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.80% of the stock is currently owned by company insiders.

Cencora Stock Down 1.3 %

Shares of NYSE:COR opened at $240.24 on Monday. The company has a 50 day moving average of $232.62 and a 200-day moving average of $231.03. Cencora, Inc. has a one year low of $194.23 and a one year high of $251.56. The stock has a market cap of $47.34 billion, a price-to-earnings ratio of 31.99, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.92%. Cencora’s payout ratio is presently 27.16%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.